about
Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patientsDifferent patterns of HIV-1 DNA after therapy discontinuation.Human immunodeficiency virus type 1 interaction with the membrane of CD4+ cells induces the synthesis and nuclear translocation of 70K heat shock proteinHuman T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological resultsHIV-1 negatively affects the survival/maturation of cord blood CD34(+) hematopoietic progenitor cells differentiated towards megakaryocytic lineage by HIV-1 gp120/CD4 membrane interaction.Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages.HIV-1 subtype C transmission network: the phylogenetic reconstruction strongly supports the epidemiological data.Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histoculturesHIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells.Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance.High prevalence of serum antibody against human T cell leukemia virus type I (HTLV-I) among the Bismam Asmat population (Indonesian New Guinea).High-throughput genotyping of high-risk Human Papillomavirus by MALDI-TOF Mass Spectrometry-based method.IFI16 Expression Is Related to Selected Transcription Factors during B-Cell Differentiation.Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.Molecular and phylogenetic analysis of HIV-1 variants circulating in ItalyGenotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupAntiretroviral molecules and cardiovascular diseases.HIV-related mechanisms in atherosclerosis and cardiovascular diseases.HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.V3 net charge: additional tool in HIV-1 tropism prediction.Human immunodeficiency virus (HIV) seropositivity in intravenous (i.v.) drug abusers in three cities of Italy: possible natural history of HIV infection in i.v. drug addicts in Italy.Modulation of CD4, CXCR-4, and CCR-5 makes human hematopoietic progenitor cell lines infected with human herpesvirus-6 susceptible to human immunodeficiency virus type 1.Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients.HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation.Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.Differentially expressed genes in HIV-1 tat-expressing CD4(+) T-cell line.In a human lymphomyeloid progenitor cell line (KG-1) HIV-1 gp120 binds to chemokine-receptors CXC-R4 and CCR5, only in the presence of CD4.Human T-cell leukemia virus type II directly acts on CD34+ hematopoietic precursors by increasing their survival potential. envelope-associated HLA class II molecules reverse this effect.Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients.Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy.Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo.The CD4 receptor plays essential but distinct roles in HIV-1 infection and induction of apoptosis in primary bone marrow GPIIb/IIIa+ megakaryocytes and the HEL cell line.In situ polymerase chain reaction technique revealed by flow cytometry as a tool for gene detection.The lack of susceptibility to HIV-1 infection in human hematopoietic progenitor TF-1 cell line correlates with the absence of LFA-1 (CD11a) surface adhesion molecule.In vitro exposure to human immunodeficiency virus type 1 induces apoptotic cell death of the factor-dependent TF-1 hematopoietic cell line.Levels of free purine nucleotides in continuous T-cell lines infected with virus HIV-1.Enhancement of HIV-1 marker detection in cell cultures treated with mild heat-shock.
P50
Q24795766-D5FF7B28-4FFD-4EF6-8DF8-F2C2901FE26FQ24816681-2FEAE88F-2092-4B32-84B8-BB6D1994B3CFQ28237289-6850707F-3107-4BED-BF78-F533C48BF7F9Q33235267-4F121637-F97A-49F6-B434-D7258ECC3BE0Q33373320-EEFAE2E3-595B-46BC-ACA6-05C393F2FEC9Q33411216-5C888CC1-F8E9-4A17-A9FB-DB73A8F5ACC2Q33558274-E2798F55-2510-4CCC-8A26-57EC9141A35BQ34158739-58C8CD45-C6DD-44AB-92F0-0E0E7699D48FQ34247524-A26A81AE-C41B-4FD0-A11B-9296C1DCC2AFQ35014689-FD26ED0C-8E38-43BE-9CCD-097E8F1ECADCQ35068359-8E95D9B8-E9B3-4C20-A24E-EF7F31F17AFEQ35574791-AD8C4B72-0913-4E45-AB7F-74AE7E0185D8Q35612463-93B77158-7C2E-4495-9BFB-25CBD6C78C55Q35621728-B1DE4DA4-44B2-4B70-8BEE-F85D5B0ED197Q35818113-D747BA4C-A301-443F-9E34-510D43F4C5EAQ36535977-BF51B6E5-7BF2-4CDF-A1EC-6397A22A0882Q36981930-CD914ECB-8D65-4AF7-BAC6-C1C92C9738BDQ37530942-8804AF89-DA4B-42C8-A3B2-78F3F9D7A5E8Q38056427-228D23CC-0C5F-46A9-BE72-15CE09738FA4Q38105203-B1E5A348-3D22-4BF3-9836-64BB5F56F731Q38390465-CD1B5EE6-14B2-443A-B6ED-1EB1FD6F4455Q38913832-5DFBCCE7-B446-4DEB-8A2D-6A63A634A408Q39263379-64051D3E-93FE-4DB6-8A1B-09B9702DC771Q39299586-5EE34B53-CCA4-4EED-8F57-3CC4DE7A3570Q39560525-96679270-ACB4-4E32-85FD-8133D201C5E8Q39810236-CE75C8A8-BED0-41C8-9FF0-E4EB45432213Q39958121-5A521864-AECB-4C30-A7BA-C7236768A35AQ40558759-BA7EDF98-027A-4EB3-9AFA-80E6304F3EA9Q40686654-FC8CDBF6-0EAA-4C02-9855-B02EB0718F33Q40919119-A52058B1-78E1-4D49-8D15-717819AB1DB3Q41050755-8065A26D-C20F-43E4-B029-E663EAC4AFA6Q41121234-F0181FDA-9F06-4874-B168-BBB8999E1270Q41261486-038FEE84-3280-478E-9D0D-85BAB6003CE5Q41267357-B6769DA7-9564-4610-870F-9AAB346B3A9FQ41287953-6DA350F3-7BB8-4BFA-9E97-62F066601F06Q41327867-3AD53A94-C893-4E05-835B-E7931305364CQ41393870-FE1458A4-274C-4ACC-98FB-A344E6E30357Q41507525-441DCAA6-CBD3-48DB-9F55-591F26F3D170Q41586760-7A300D10-14BA-4EA6-A2AB-6E89C55CABB1Q41757351-5DBAD967-8096-4928-AD82-3C71551AD879
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maria Carla Re
@ast
Maria Carla Re
@en
Maria Carla Re
@es
Maria Carla Re
@nl
Maria Carla Re
@sl
type
label
Maria Carla Re
@ast
Maria Carla Re
@en
Maria Carla Re
@es
Maria Carla Re
@nl
Maria Carla Re
@sl
prefLabel
Maria Carla Re
@ast
Maria Carla Re
@en
Maria Carla Re
@es
Maria Carla Re
@nl
Maria Carla Re
@sl
P106
P21
P31
P496
0000-0003-1486-9033